# Curetis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/curetis

- Industry: Healthcare
- Headquarters: Holzgerlingen, Germany
- Website: www.curetis.com
- Total disclosed funding: $74M
- Latest round: Series B (Jun 1, 2014)
- Investors on record: 11

## About

Curetis AG specializes in rapid molecular diagnostics, focusing on the detection of infectious diseases and antimicrobial resistance. Their innovative solutions enhance healthcare efficiency and improve patient outcomes through timely diagnostics.Curetis AG is a molecular diagnostics company founded in 2007 and headquartered in Holzgerlingen, Germany. The firm focuses on developing and commercializing innovative diagnostic solutions. The company's CEO, Albert Weber, leads its operations. Curetis AG raised EUR 40 million in an IPO on November 11, 2015, offering 4 million shares at EUR 10 per share. To date, the company has engaged in 11 deals, all of which contribute to its strategic growth and market presence.Curetis GmbH's core product, the Unyvero A50 Solution, is a rapid molecular diagnostic system designed to detect a wide range of pathogens and antimicrobial resistance markers. It delivers results in less than five hours with only two minutes of hands-on time, enabling healthcare professionals to make swift, informed treatment decisions in managing severe infections. The system caters to hospitals, laboratories, and healthcare providers across Europe, North America, and Asia, with five innovative applications addressing major clinical syndromes and accommodating various sample types for diverse diagnostic needs.In the most recent year, Curetis GmbH reported revenue of EUR 2,115,755.70 for 2020, with an EBITDA of EUR -8,733,612. The revenue model primarily revolves around the sale of the Unyvero A50 diagnostic system and related consumables, serving clients through direct sales and partnerships with healthcare institutions and diagnostic laboratories.Curetis AG aims to expand its product offerings by launching new applications for its Unyvero A50 system, targeting an increase in diagnostic capabilities over the next few years. The company also plans to penetrate new geographical markets, focusing on regions in Asia and North America by 2025. The funds raised in the EUR 40 million IPO will be allocated to support these initiatives and enhance infrastructure, ensuring efficient market entry and product delivery.

## Funding rounds

- Series B, Jun 1, 2014, $10M — EQT Life Sciences, CD Capital, Forbion, Roche Venture Fund, Aeris Capital, Biomedical Investments
- Series B, Apr 22, 2013, $16M — HBM Partners, EQT Life Sciences, KfW Banking Group, BioMed Partners, Forbion, Roche Venture Fund, Aeris Capital, CD-Venture
- Series A, Oct 26, 2011, $13M — Julip Run Capital, Forbion, Roche Venture Fund
- Series A, May 17, 2011, $6.5M — EQT Life Sciences, KfW Banking Group, BioMed Partners, Aeris Capital, CD-Venture
- Series A, Dec 3, 2009, $28M — EQT Life Sciences, KfW Banking Group, BioMed Partners, Aeris Capital

## Investors

- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A, Series B
- KfW Banking Group — Series A, Series B
- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series A, Series B
- Aeris Capital — Series A, Series B
- CD-Venture (https://capitalatlas.ai/funds/cd-venture) — Series A, Series B
- Julip Run Capital (https://capitalatlas.ai/funds/julip-run-capital) — Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A, Series B
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series A, Series B
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B
- CD Capital — Series B
- Biomedical Investments — Series B